Become A Featured Company

Top 10 Medical Marijuana Stocks

Rachelle Gordon

April 26th, 2017

News, Top News

top 10

The legal cannabis market is growing at a rapid pace, with analysts predicting that pot could grow to a value of over $50 billion in only ten short years. Knowing this, many people from across the political spectrum are looking to invest. It is still a bit of a risky time to get into the marijuana market, as the plant remains illegal at the federal level. However, most experts believe cannabis is here to stay, so why not invest now? Here’s a list of the top 10 medical marijuana stocks you may want to look into.

#1: GW Pharmaceuticals Plc (NASDAQ:GWPH)

GW Pharmaceuticals has been getting a lot of attention recently due to the development of Epidiolex, a synthetic cannabinoid medication for epilepsy. The drug is performing well in trials, and if approved by the FDA, could be worth more than $1 billion within a few years.

#2: INSYS Therapeutics (NASDAQ:INSY)

Much like GW, INSYS is a biotech firm dedicated to creating treatments based on cannabinoids. The majority of their products are delivered sublingually (via a spray), offering both patients and caregivers a more efficient way to medicate. Currently, their main focus is on developing their cannabidiol spray to meet the needs of those suffering from Dravet Syndrome, infantile spasms, and Lennox-Gastaut Syndrome.

#3: AXIM Biotechnologies Inc. (OTCQB:AXIM)

Another company looking to change the face of how medicine is delivered, AXIM strives to be on the cutting-edge of cannabinoid therapies. The firm is currently developing the world’s first CBD/THC controlled-release functional chewing gum, called MedChewRX. The drug is meant for patients with multiple sclerosis to help effectively treat chronic pain and spasticity issues.

#4: Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba is focused on creating transdermal cannabinoid therapies for a multitude of illnesses, including fibromyalgia, osteoarthritis, refractory epilepsy, Fragile X syndrome, and peripheral neuropathic pain. Their synthetic cannabidiol gel is currently in Phase 2 trials and showing efficacy in patients.

#5: Cannabics Pharmaceuticals Inc. (OTCQB:CNBX)

Looking to help promote the use of cannabinoids in cancer treatments, Cannabics Pharmaceuticals is currently involved in clinical testing in Israel for palliative treatment using their proprietary capsules. The therapy is used to help promote appetite and weight-gain in patients with advanced-stage cancers.

#6: Cannabis Science Inc. (OTCPK:CBIS)

This Colorado Springs-based biotech firm is committed to creating effective cannabinoid-based therapies for a wide variety of ailments. Cannabis Science is developing treatments for skin cancer, HIV, PTSD, sleep disorders, and other neurobehavioral issues.

#7: Cure Pharmaceutical Holding Corp. (OTCQB:CURR)

Cure Pharmaceutical mainly focuses on developing drug delivery methods using their proprietary molecule makeup. Their flagship product, CureFilm, is a sublingual delivery method that can be used with a variety of different cannabinoid treatments.

#8: OWC Pharmaceutical Research Corp. (OTCQB:OWCP)

One World Cannabis (OWC) has several cannabis-based therapy products in development and on the market. Their tablets and topicals can be purchased across the globe, including the 29 states where medical cannabis has been legalized. The firm is also researching new treatments for multiple myeloma, psoriasis, fibromyalgia, migraine and PTSD.

#9: 22nd Century Group (NYSEMKT:XXII)

This biotechnology firm is a bit different than others on the list. 22nd Century Group uses genetic engineering to modify nicotine molecules, and therefore reduce the harm caused by smoking. The company added cannabis as a focus in order to help develop cannabinoid-specific products, much like they have done in the past with nicotine.

#10: PharmaCyte Biotech Inc. (OTCQB:PMCB)

PharmaCyte is on the forefront of cannabinoid-based cancer and diabetes therapies. Their patented “Cell-in-a-Box” technology allows for live cells to be isolated within protective capsules and nourished – in this case, from cannabinoids. This targeted therapy may be used with many different diseases, exciting researchers and investors alike.

To learn more about cannabis investments, sign-up for our free newsletter using the form to the right.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Rachelle Gordon

Rachelle Gordon is a Minneapolis-based writer. Find her online at www.rachellegordon.net.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading